ZBTB38 (Zinc Finger And BTB Domain Containing 38)

This integrative genomic analysis provides robust evidence for causal relationships between specific gene expression patterns in breast mammary tissue and breast cancer risk.

This study identified five key m5C-related genes, unraveled their link to immune cells, and developed an accurate RPL diagnostic model. The RPL patients are innovatively divided into two clusters, and the difference of their immune microenvironment is analyzed. This study offers a fresh perspective for examining biomarkers and potential therapeutic targets for RPL.

Drug sensitivity analysis further revealed that the low-risk group exhibited enhanced responses to epirubicin (P<0.001), irinotecan (P<0.001), and Poly(ADP-ribose) polymerase (PARP) inhibitors (niraparib P<0.001, olaparib P<0.001), suggesting potential therapeutic implications. Our findings suggest that the prognostic model, which is based on MBD3 and UHRF1 expression, may improve prognostic stratification in PCA patients and assess drug efficacy. This model represents a step toward epigenetic-based oncology, though its impact on treatment decisions remains to be validated.

Finally, a VTE-related risk score model was constructed, indicating better outcomes in the low-VTE risk score group. This study demonstrated that VTE is closely associated with BC development and identified potential molecular pathways linking the two conditions.

Interactive drugs were identified, including amoxicillin, atenolol, infliximab, colchicine, propionyl-L-carnitine, BMN-111, and tamoxifen, which were known to have a positive effect on height. Our results suggest that many genes have causal effects on height. By interrogating drug-gene interactions, interactive drugs have been identified as having both positive and negative effects on growth, which would help make clinical decisions.

In summary, our research has revealed a repertoire of genes within diverse immune cells associated with breast cancer. KCNN4 gene in non-classical MONOcytes (MONOnc) exhibited a negative association with overall breast cancer and its subtypes, which was identified as a potential drug target for breast cancer, opening up new avenues for therapeutic interventions.

Changes in the methylation and transcriptional levels of ZBTB38, ZC3H3, FOXK1, and KAZN are important for the development of fibrosis and HCC; and are therefore potential therapeutic targets and diagnostic tools for cirrhosis and HCC.

Collectively, miR-200c and miR-141 are likely to be upregulated in CSF exosomes after chemotherapy in patients with PCNSL, highlighting their potential as reliable liquid biopsy biomarkers for PCNSL diagnosis and chemotherapy efficacy monitoring.

The study provides evidence that DNA methylation regulators play a significant role in the prognosis of ccRCC and the developed DNA methylation regulator-based signature could effectively predict patient outcome.

DNA methylation diagnostics criteria using up to 6 of 8 CpG sites for LPP, FOXO1, RNF4, EXOC6B, CCPG1, RREB1 and ZBTB38 may be applicable to recurrence risk estimation for patients aged 40 years or less with endometrial cancer, regardless of tumor cell content, even if formalin-fixed paraffin-embedded biopsy or curettage materials are used.

Somatic mutations, mRNA expressions, miRNA expressions, metabolites and methylation were related to the resistance of cisplatin. The models we created could help in the prediction of the reaction and prognosis of patients given platinum-based chemotherapies.